{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:47:21Z","timestamp":1792115241482,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01578-9","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:05:59Z","timestamp":1789524359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Postoperative ctDNA-Guided Adjuvant Therapy in Resected Colorectal Cancer: A Systematic Review and Meta-analysis of Prognostic Validity Versus Treatment-Decision Utility"],"prefix":"10.1007","volume":"57","author":[{"given":"Zheng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"1578_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41416-022-02017-9","volume":"128","author":"LG Faulkner","year":"2023","unstructured":"Faulkner LG, Howells LM, Pepper C, Shaw JA, Thomas AL. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128:297\u2013309. https:\/\/doi.org\/10.1038\/s41416-022-02017-9.","journal-title":"Br J Cancer"},{"key":"1578_CR2","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27:5586\u201394.","journal-title":"Clin Cancer Res"},{"key":"1578_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with colorectal cancer to detect minimal residual disease and relapse. JAMA Oncol. 2019;5:1124\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0528.","journal-title":"JAMA Oncol"},{"key":"1578_CR4","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30:1804\u201312.","journal-title":"Ann Oncol"},{"key":"1578_CR5","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in colorectal cancer: biology, detection, and clinical implications. Clin Cancer Res. 2022;28:3636\u201347.","journal-title":"Clin Cancer Res"},{"key":"1578_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114159","volume":"207","author":"N Verschoor","year":"2024","unstructured":"Verschoor N, Bos MK, Oomen-de Hoop E, Martens JWM, Sleijfer S, Jager A, et al. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: the importance of trial design. Eur J Cancer. 2024;207:114159. https:\/\/doi.org\/10.1016\/j.ejca.2024.114159.","journal-title":"Eur J Cancer"},{"key":"1578_CR7","first-page":"1011","volume":"132","author":"E Sanderson","year":"2025","unstructured":"Sanderson E, Newton AD, Hall PS, et al. The emerging clinical utility of ctDNA to guide adjuvant therapy in colorectal cancer. Br J Cancer. 2025;132:1011\u201320.","journal-title":"Br J Cancer"},{"key":"1578_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01175","author":"ASCO Expert Panel","year":"2024","unstructured":"ASCO Expert Panel. Clinical utility of circulating tumor DNA assays in solid tumors: considerations for practice and trial design. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.01175.","journal-title":"J Clin Oncol"},{"key":"1578_CR9","doi-asserted-by":"publisher","first-page":"175883592412661","DOI":"10.1177\/17588359241266164","volume":"16","author":"A Kramer","year":"2024","unstructured":"Kramer A, Greuter MJE, Degeling K, et al. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer. Ther Adv Med Oncol. 2024;16:17588359241266164. https:\/\/doi.org\/10.1177\/17588359241266164.","journal-title":"Ther Adv Med Oncol"},{"key":"1578_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40273-021-01047-0","volume":"39","author":"YH To","year":"2021","unstructured":"To YH, Degeling K, Kosmider S, et al. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics. 2021;39:959\u201370. https:\/\/doi.org\/10.1007\/s40273-021-01047-0.","journal-title":"Pharmacoeconomics"},{"key":"1578_CR11","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2026","author":"National Comprehensive Cancer Network","year":"2026","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2026. NCCN; 2026."},{"key":"1578_CR12","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343\u201351.","journal-title":"N Engl J Med"},{"key":"1578_CR13","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andre","year":"2015","unstructured":"Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176\u201387.","journal-title":"J Clin Oncol"},{"key":"1578_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177\u201388.","journal-title":"N Engl J Med"},{"key":"1578_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"JA Meyerhardt","year":"2022","unstructured":"Meyerhardt JA, Shi Q, Fuchs CS, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40:892\u2013910.","journal-title":"J Clin Oncol"},{"key":"1578_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:329\u201359.","journal-title":"J Natl Compr Canc Netw"},{"key":"1578_CR17","first-page":"1527","volume":"32","author":"F Loupakis","year":"2021","unstructured":"Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing surgery. Ann Oncol. 2021;32:1527\u201335.","journal-title":"Ann Oncol"},{"key":"1578_CR18","first-page":"1055","volume":"33","author":"TV Henriksen","year":"2022","unstructured":"Henriksen TV, Tarazona N, Reinert T, et al. Circulating tumor DNA for detection and molecular characterization of recurrence in colorectal cancer. Ann Oncol. 2022;33:1055\u201367.","journal-title":"Ann Oncol"},{"key":"1578_CR19","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.2020.38.15_suppl.4610","volume":"38","author":"A Dasari","year":"2020","unstructured":"Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: clinical considerations and future directions. J Clin Oncol. 2020;38:1780\u20138.","journal-title":"J Clin Oncol"},{"key":"1578_CR20","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2200075.","journal-title":"N Engl J Med"},{"key":"1578_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31:1509\u201318. https:\/\/doi.org\/10.1038\/s41591-025-03579-w.","journal-title":"Nat Med"},{"key":"1578_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04030-w","author":"J Tie","year":"2025","unstructured":"Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-04030-w.","journal-title":"Nat Med"},{"issue":"3suppl","key":"1578_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JCO.2024.42.3_suppl.5","volume":"42","author":"VK Morris","year":"2024","unstructured":"Morris VK, Yothers G, Kopetz S, et al. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II\/III study. J Clin Oncol. 2024;42(3suppl):5. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.5.","journal-title":"J Clin Oncol"},{"issue":"4suppl","key":"1578_CR24","doi-asserted-by":"publisher","first-page":"LBA22","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA22","volume":"43","author":"H Bando","year":"2025","unstructured":"Bando H, Watanabe J, Kotaka M, et al. The ALTAIR study: a randomized, double-blind, phase III study comparing trifluridine\/tipiracil versus placebo in patients with molecular residual disease following curative resection of colorectal cancer. J Clin Oncol. 2025;43(4suppl):LBA22. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.LBA22.","journal-title":"J Clin Oncol"},{"key":"1578_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047831","volume":"11","author":"PM Kasi","year":"2021","unstructured":"Kasi PM, Sawyer S, Guilford J, et al. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open. 2021;11:e047831. https:\/\/doi.org\/10.1136\/bmjopen-2020-047831.","journal-title":"BMJ Open"},{"key":"1578_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12885-023-10699-4","volume":"23","author":"S Slater","year":"2023","unstructured":"Slater S, Bryant A, Chen HC, et al. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: TRACC Part C. BMC Cancer. 2023;23:257. https:\/\/doi.org\/10.1186\/s12885-023-10699-4.","journal-title":"BMC Cancer"},{"key":"1578_CR27","doi-asserted-by":"publisher","unstructured":"Schraa SJ, van Rooijen KL, van der Kruijssen DEW, PLCRC-MEDOCC group, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020;20:790. https:\/\/doi.org\/10.1186\/s12885-020-07252-y.","DOI":"10.1186\/s12885-020-07252-y"},{"key":"1578_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.dld.2020.04.010","volume":"52","author":"J Taieb","year":"2020","unstructured":"Taieb J, Benhaim L, Puig PL, et al. Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: the CIRCULATE-PRODIGE 70 trial. Dig Liver Dis. 2020;52:730\u20133. https:\/\/doi.org\/10.1016\/j.dld.2020.04.010.","journal-title":"Dig Liver Dis"},{"key":"1578_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clcc.2021.09.006","volume":"21","author":"G Folprecht","year":"2022","unstructured":"Folprecht G, Reinacher-Schick A, Weitz J, et al. The CIRCULATE Trial: circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation (AIO-KRK-0217). Clin Colorectal Cancer. 2022;21:170\u20134. https:\/\/doi.org\/10.1016\/j.clcc.2021.09.006.","journal-title":"Clin Colorectal Cancer"},{"key":"1578_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/0284186X.2019.1711170","volume":"59","author":"A Jakobsen","year":"2020","unstructured":"Jakobsen A, Andersen RF, Hansen TF, et al. IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Acta Oncol. 2020;59:336\u201341. https:\/\/doi.org\/10.1080\/0284186X.2019.1711170.","journal-title":"Acta Oncol"},{"issue":"4_suppl","key":"1578_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS310","volume":"43","author":"NRG Oncology","year":"2025","unstructured":"NRG Oncology. NRG-GI008: colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA). J Clin Oncol. 2025;43(4_suppl):TPS310. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.TPS310.","journal-title":"J Clin Oncol"},{"key":"1578_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1578_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Sawada K, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29:127\u201334. https:\/\/doi.org\/10.1038\/s41591-022-02115-4.","journal-title":"Nat Med"},{"key":"1578_CR34","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"key":"1578_CR35","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915\u201320. https:\/\/doi.org\/10.1111\/cas.14926.","journal-title":"Cancer Sci"},{"key":"1578_CR36","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024."},{"key":"1578_CR37","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1578_CR38","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute;"},{"key":"1578_CR39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"1578_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: rating the quality of evidence - study limitations. J Clin Epidemiol. 2011;64:407\u201315.","journal-title":"J Clin Epidemiol"},{"key":"1578_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6219.","journal-title":"Sci Transl Med"},{"key":"1578_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01089-z","volume":"14","author":"G Chen","year":"2021","unstructured":"Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hematol Oncol. 2021;14:80. https:\/\/doi.org\/10.1186\/s13045-021-01089-z.","journal-title":"J Hematol Oncol"},{"key":"1578_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2022.04.010","volume":"169","author":"Y Li","year":"2022","unstructured":"Li Y, Mo S, Zhang L, Ma X, Hu X, Huang D, et al. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: a prospective cohort study. Eur J Cancer. 2022;169:198\u2013209. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.010.","journal-title":"Eur J Cancer"},{"key":"1578_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2021.09.004","volume":"159","author":"L Benhaim","year":"2021","unstructured":"Benhaim L, Bouche O, Normand C, et al. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). Eur J Cancer. 2021;159:24\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.004.","journal-title":"Eur J Cancer"},{"key":"1578_CR45","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5:1710\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3616.","journal-title":"JAMA Oncol"},{"key":"1578_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03884-3","volume":"21","author":"Z Gao","year":"2023","unstructured":"Gao Z, Huang D, Huang H, Yang Y, An K, Ding C, et al. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer. J Transl Med. 2023;21:80. https:\/\/doi.org\/10.1186\/s12967-023-03884-3.","journal-title":"J Transl Med"},{"issue":"3_suppl","key":"1578_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2024.42.3_suppl.12","volume":"42","author":"DYNAMIC-Rectal investigators","year":"2024","unstructured":"DYNAMIC-Rectal investigators. Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: the randomized AGITG DYNAMIC-Rectal study. J Clin Oncol. 2024;42(3_suppl):12. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.12.","journal-title":"J Clin Oncol"},{"key":"1578_CR48","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-19-3809","volume":"26","author":"VK Morris","year":"2020","unstructured":"Morris VK, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor in patients with BRAF V600E-mutated colorectal cancer after curative-intent therapy: implications for MRD-guided trials. Clin Cancer Res. 2020;26:3417\u201325.","journal-title":"Clin Cancer Res"},{"key":"1578_CR49","first-page":"2137","volume":"29","author":"S Kopetz","year":"2023","unstructured":"Kopetz S, Guthrie KA, Morris VK, et al. Randomized trial platforms for ctDNA-guided adjuvant therapy in colorectal cancer: design considerations for MRD-positive and MRD-negative populations. Clin Cancer Res. 2023;29:2137\u201344.","journal-title":"Clin Cancer Res"},{"key":"1578_CR50","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926\u201330.","journal-title":"Science"},{"key":"1578_CR51","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446\u201351.","journal-title":"Nature"},{"key":"1578_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"1578_CR53","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36:1631\u201341.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1578_CR54","first-page":"3505","volume":"42","author":"PM Kasi","year":"2024","unstructured":"Kasi PM, Fehringer G, Taniguchi H, et al. Impact of ctDNA testing on real-world adjuvant decision-making in stage II and III colorectal cancer: BESPOKE CRC interim analysis. J Clin Oncol. 2024;42(16suppl):3505.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01578-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:06:05Z","timestamp":1789524365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01578-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1578"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01578-9","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published aggregate data and did not involve individual patient-level data.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used AI-assisted language tools for language polishing, formatting assistance, and quality checking. The authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Generative AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"220"}}